In the era of Human Papillomavirus (HPV) vaccination, a lot of misunderstanding still exists among healthcare professionals and patients regarding HPV infection. The purpose of this review is to synthesize the clinical molecular mechanisms that contribute to HPV-mediated cervical carcinogenesis, as well as to appraise the current status of new biomarkers and technologies in terms of available data on clinical applications and future promises.
ParkinD. M.BrayF.FerlayJ.PisaniP.Global cancer statistics, 2002. CA Cancer J Clin55, 74–108 (2005).
2.
JemalA.SiegelR.WardE.MurrayT.XuJ.ThunM. J.Cancer statistics 2007. CA Cancer J Clin57, 43–66 (2007).
3.
BrayF.FerlayJ.PisaniP.Estimating the world cancer burden: Globocan 2000. Int J Cancer94, 153–156 (2001).
4.
Cervix Cancer Screening. Lyons: International Agency for Research on Cancer (2005).
5.
ArbynM.RaifuA. O.AutierP.FerlayJ.Burden of cervical cancer in Europe: Estimates for 2004. Ann Oncol18, 1708–1715 (2007).
6.
StolerM. H.SchiffmanM.Interobserver reproducibility of cervical cytologic and histologic interpretations: Realistic estimates from the ASCUS-LSIL Triage Study. JAMA285, 1500 (2001).
7.
SasieniP. D.CuzickJ.Lynch-FrameryE.Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. Br J Cancer73, 1001–1005 (1996).
8.
International Agency for Research on Cancer (IARC) Working Group on the Evaluation of Carcinogenic Risks to Humans.Human Papillomaviruses. Lyon, France: World Health Organization. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 64 (1995).
9.
ArbynM.BuntinxF.Van RanstM.ParaskevaidisE.Martin-HirschP.DillnerJ.Virologic Versus Cytologic Triage of Women With Equivocal Pap Smears: A Meta-analysis of the Accuracy To Detect High-Grade Intraepithelial Neoplasia. J Natl Cancer Inst18, 280–287 (2004).
10.
CuzickJ.Role of HPV testing in clinical practice. Virus Res89, 263–269 (2002).
11.
Duarte-FrancoE.FrancoE. L.Cancer of the uterine cervix. BMC Women's Health4 (Suppl 1), S13 (2004).
12.
StolerM. H.SchiffmanM.Toward optimal laboratory use. Interobserver reproducibility of cervical cytology and hystologic interpretations. Realistic estimates from the ASCUS/LSIL Triage Study. JAMA285, 1500–1505 (2001).
13.
RenshawA. A.DaveyD. D.BirdsongG. G.WalshM.StyerP. E.ModyD. R.SolomonD.Precision in gynaecologic cytologic interpretation: A study from the College of American Pathologists Interlaboratory Comparison Program in ervicovaginal Cytology. Arch Pathos Lab Med127, 1413–1420 (2003).
14.
ConfortiniM.CarozziF.PalmaDalla P.GhiringelloB.ParisioF.PrandiS.RoncoG.CiattoS.MontanariG.GISCI Working Group for Cervical Cytology. Interlaboratory reproducibility of atypical squamous cells of undetermined significance report: A national survey. Cytopathology14, 263–268 (2003).
15.
CibasE. S.AlonzoT.A.AustinR. M.BolickD. R.GlantM. D.HenryM. R.MoriartyA. T.MolinaJ. T.RushingL.SlowmanS. D.TornoR.EisenhutC. C.The MonoPrep Pap test for the detection of cervical cancer and its precursors. Part I: Results of a multicenter clinical trial. Am J Clin Pathol129, 193–201 (2008).
16.
AbulafiaO.PezzulloJ. C.ShererD. M.Performance of ThinPrep liquid-based cervical cytology in comparison with conventionally prepared Papanicolaou smears: A quantitative survey. Gynecol Oncol90, 137–144 (2003).
17.
DaveyE.BarrattA.IrwingL.ChanS. F.MacaskillP.MannesP.SavilleA. M.Effect of study design and quality on unsatisfactory rates, cytological classifications, and accuracy in liquid-based versus conventional cervical cytology: A systematic review. Lancet367, 122–132 (2006).
18.
DaveyE.d'AssuncaoJ.IrwigL.MacaskillP.ChanS. F.RichardsA.FarnsworthA.Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: Prospective study. BMJ335, 28–35 (2007).
19.
NanceK. V.Evolution of Pap testing at a community hospital — a ten years experience. Diagnostic Cytopathology35, 148–153 (2007).
20.
PapilloJ. L.St JohnT. L.LeimanG.Effectiveness of the ThinPrep Imaging System: Clinical experience in a low risk screening population. Diagnostic Cytopathology36, 155–160 (2008).
21.
BernsteinS. J.Sanchez-RamosL.NdubisiB.Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: A metaanalysis of prospective studies comparing cytologic diagnosis and sample adeguacy. Am J Obstet Gynecol185, 308–317 (2001).
22.
KlinkhamerP. J. J. M.MeerdingW. J.RosierP. F. W. M.HanselaarA. G. J. M.Liquid based cervical cytology: A review of the literature with methods of evidence based medicine. Cancer99, 263–271 (2003).
CliffordG. M.GallusS.HerreroR.Worldwide distribution of human Papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV Prevalence Survey: A pooled analysis. Lancet366, 991–998 (2005).
26.
BoschF. X.LorinczA.MunozN.MeijerC. J.ShahK. V.The causal relation between human papillomavirus and cervical cancer. J Clin Pathol55, 244–265 (2002).
27.
BaayM. F.SmitsE.TjalmaW. A.Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women. Int J Cancer108, 258–261 (2004).
28.
MunozN.MendezF.PossoH.MolanoM.Van den BruleA.RonderosM.MeijerC.MunozA., for the Instituto National de Cancerologia HPV Study Group. Incidence, duration and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis190, 234–242 (2004).
29.
MuñozN.CastellsagueX.de GonzalezA. B.GissmanL.Chapter I: HPV in the etiology of human cancer. Vaccine24 (Suppl 3), S1-S7 (2006).
30.
CliffordG. M.SmithJ. S.PlummerM.MuñozN.FranceschiS.Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer88, 63–73 (2003).
31.
KrausI.MoldenT.HolmR.LieA. K.KarlsenF.KristensenG. B.SkomedalH.Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol44, 1310–1317 (2006).
32.
De SanjoséS.DiazM.CastellsaguéX.CliffordG.BruniL.MuñozN.BoschF. X.Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis7, 453–459 (2007).
33.
zur HausenH.Viruses in human cancers. Science254, 1176–1273 (1991).
34.
SolomonD.Chapter 14: Role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr31, 97–106 (2003).
35.
SmithJ. S.LindsayL.HootsB.KeysJ.FranceschiS.WinerR.Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer121, 621–632 (2007).
36.
DillnerJ.The serological response to Papillomavirus. Sem Cancer Biol9, 423–430 (1999).
37.
HopmanA. H.KampsM. A.SmedtsF.SpeelE. J.HerringtonC. S.RamaekersF. C.HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. Int J Cancer115, 419–428 (2005).
38.
CaussyD.OrrW.DayaA. D.RothP.ReevesW.RawlsW.Evaluation of methods for detection human Papillomavirus deoxiribonucleotide sequences in clinical specimens. J Clin Microbiol26, 236–243 (1988).
39.
SeedlacekT. V.Advances in the diagnosis and treatment of human papillomavirus infections. Clin Obstet Gynecol42, 206–220 (1999).
40.
Van DoornL. J.KleterB.QuintW. G.Molecular detection and genotyping of human papillomavirus. Expert Rev Mol Diagn1, 394–402 (2001).
41.
BouletG. A. V.HorvathC. A. J.BerghmansS.BogersnJ.Cancer Epidemiol Biomarkers Prev17, 810–817 (2008).
42.
PerronsC.JelleyR.KleterB.QuintW.BrinkN.Detection of persistent high risk human papillomavirus infection with Hybrid Capture II and specific SPF10/LiPA. J Clin Virol32, 278–285 (2005).
43.
ChanP. K.CheungT. H.TamA. O.LoK. W.YimS. F.YuM. M.ToK. F.WongY. F.CheungJ. L.ChangD. P.HuiM.IpM.Biases in human Papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer118, 243–245 (2006).
44.
MonsonegoJ.BohbotJ. M.PolliniG.Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol99, 160–168 (2005).
45.
SandriM. T.LentatiP.BeniniE.Comparison of the Digene HC2 Assay and the Roche AMPLICOR human Papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol44, 2141–2146 (2006).
46.
KulusingamS. L.HughesJ. P.KiviatN. B.MaoC.WeissN. S.KuypersJ. M.Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: Comparison of sensitivity, specificity, and frequency of referral. JAMA288, 1749–1757 (2002).
47.
ShiffmanM.WheelerC.DasguptaA.SalomonD.CastleP. E., for the ALTS Group. A comparison of a prototype PCR assay and Hybrid Capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou smears. Am J Clin Pathol124, 1–11 (2005).
48.
CarozziF. M.Del MistroA.ConfortiniM.SaniC.PulitiD.TrevisanR.Reproducibility of HPV DNA testing by Hybrid Capture 2 in a screening setting: Intralaboratory and interlaboratory quality control in seven laboratories partecipating in the same clinical trial. Am J Clin Pathol124, 1–6 (2005).
49.
CubieH. A.MooreC.WallerM.MossS., on behalf of the National Cervical Screening Committee LBC/HPV Pilot Steering Group. The development of a quality assurance program for HPV testing with the UK NHS cervical screening LBC/HPV studies. J Clin Virol33, 287–292 (2005).
50.
CuschieriK. S.WhitleyM. J.CubieH. A.Human papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol73, 65–70 (2004).
51.
BelinsonJ.QiaoY. L.PretoriusR.ZhangW. H.ElsonP.LiL.PanQ. J.FischerC.LorinczA.ZahniserD.Shanxi Province cervical cancer study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol83, 439–444 (2001).
52.
PalmaDalla P.PojerA.GirlandoS.HPV triage of women with atypical squamous cells of undetermined significance: A 3-year experience in an Italian organized program. Cytopathology16, 22–27 (2005).
53.
WalboomersJ. M.JacobsM. V.ManosM. M.Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol189, 12–19 (1999).
54.
DunneE. F.UngerE. R.SternbergM.McQuillanG.SwanD. C.PatelS. S.Prevalence of HPV infection among females in the United States. J Am Med Assoc297, 813–819 (2007).
55.
MunozN.BoschF. X.de SanjoseS.HerreroR.CastellsagueX.ShahK. V.Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med348, 518–527 (2003).
56.
ASCUS-LSIL Triage Study (ALTS) Group.Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol188, 1383–1387 (2003).
57.
SolomonD.SchiffmanM. H.TaroneR.Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: Baseline results from a randomized trial. J Natl Cancer Inst93, 293–297 (2001).
58.
RodriguezA. C.ShiffmanM.HerreroR.WacholderS.HidesteimA.CastleP. E.SolomonD.BurkR.Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst100, 513–517 (2008).
59.
CuzickJ.Role of HPV testing in clinical practice. Virus Research89, 263–269 (2002).
60.
CuschieriK. S.CubieH. A.The role of Human Papillomavirus testing in cervical screening. J Clin Virol32S, S34–S42s (2005).
61.
DoorbarJ.The papillomavirus life cycle. J Clin Virol32S: S7–S15 (2005).
62.
WentzensenN.VinokurovaS.von KnebelD. M.Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer in the female lower genital tract. Cancer Res64, 3878–3884 (2004).
63.
TangS. M.TaoJ. P.McCoyZheng Z. M.Jr.The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol80, 4249–4251 (2006).
64.
DoorbarJ.Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond)110, 525–541 (2006).
65.
LichtigH.AlgrisiM.BotzerL. E.AbadiT.VerbitzkyY.JackmanA.TommasinoM.ZehbeI.ShermanL.HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology350, 216–219 (2006).
66.
GuessJ. C.McCanceD. J.Decreased Migration of Langerhans Precursor-Like Cells in Response to Human Keratinocytes Expressing Human Papillomavirus Type 16 E6/E7 Is Related to Reduced Macrophage Inflammatory Protein-3 Production. Virol79, 14852–14857 (2005).
67.
BiswasS. K.SodhiA.Effect of monocyte chemoattractant protein-1 on murine bone marrow cells: Proliferation, colony-forming ability and signal transduction pathway involved. Int J Immunopathol Pharmacol15, 183–187 (2002).
68.
ScottM.NakagawaM.MoscickiA.Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol8, 209–213 (2001).
69.
DuensingS.MungerK.Mechanisms of genomic instability in human cancer: Insights from studies with human papillomavirus oncoproteins. Int J Cancer109, 157–161 (2004).
70.
RosiniS.ZappacostaR.Di BonaventuraG.CaraceniD.PillaD.Di GirolamoG.EspositoA.OrsiniT.SettaS.VizzinoM.PiccolominiM.PiccolominiR.Management and triage of women in follow-up for low-grade cervical disease: Association of HPV-DNA and RNA-based methods. Int J Immunopathol Pharmacol20, 341–347 (2007).
71.
MoldenT.NygårdJ. F.KrausI.KarlsenF.NygårdM.SkareG. B.SkomedalH.ThoresenS. Ø.HagmarB.Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer10, 973–977 (2005).
72.
KrausI.MoldenT.ErnøL. E.SkomedalH.KarlsenF.HagmarB.Human Papillomavirus oncogenic expression in the dysplastic portio: An investigation of biopsies from 190 cervical cones. Br J Cancer5, 1407–1412 (2004).
73.
LilliF. B.Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. Clin Infect Dis40, 451–457 (2005).
74.
Hernandez-HernandezD. M.Ornelas-BernalL.Guido-JimenezM.Presa-GarciaT.Varado-CabreroI.Salcedo-VargasM.Mohar-BetancourtA.Garcia-CarrancaA.Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. Gynecol Oncol90, 310–317 (2003).
75.
De OerM. A.JordanovaE. S.KenterG. G.PetersA. A.CorverW. E.TrimbosJ. B.FleurenG. J.High Human Papillomavirus oncogene mRNA expression and not viral load is associated with poor prognosis in cervical cancer patients. Clin Cancer Res13, 132–138 (2007).
76.
SwanD. C.TuckerR. A.Tortolero-LunaG.MitchellM. F.WideroffL.UngerE. R.NisenbaumR. A.ReevesW. C.IcenogleJ. P.Human papilloma (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol37, 1030–1034 (1999).
77.
ZerbiniM.VenturosiS.CriccaM.GallinellaG.De SimoneP.CostaS.SantiniD.MusianiM.Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA. J Clin Pathol54, 377–380 (2001).
78.
EstellerM.HermanJ. G.Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol196, 1–7 (2002).
EhrlichM.DNA methylation in cancer: Too much, but also too little. Oncogene21, 5400–5413 (2002).
81.
SteebergenR. D.KramerD.BraakhuisB. J.SternP. L.Verheijen R.H., Meijer C.J., Snijders P.J. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst96, 294–305 (2004).
82.
FenqQ.BalasubramanianA.HawesS. E.TiureP.SowP. S.DemA.Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst97, 273–282 (2005).
83.
LiJ.ZhangZ.BidderM.FunkM. C.NguyenL.GoodfellowP. J.RaderJ. S.IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol Oncol96, 150–158 (2005).
84.
GustafsonK. S.FurthE. E.HeiyjanD. F.FanslerZ. B.ClarkD. P.DNA methylation profiling of cervical squamous intraepithelial lesions using liquid-based cytology specimens: An approach that utilizes receiver-operating characteristic analysis. Cancer102, 259–268 (2004).
85.
WentzensenN.von knebel DoeberitzM.Biomarkers in cervical cancer screening. Dis Markers23, 315–330 (2007).
86.
LambertA. P.AnschauF.SchmittV. M.p16INK4a expression in cervical premalignant and malignant lesions. Exp Mol Pathol80, 192–196 (2006).
87.
AnderssonS.HanssonB.NormanI.GaberiV.MintsM.HjerpeA.KarisenF.JohanssonB.Expression of E6/E7 mRNA from “High risk” Human Papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol29, 705–711 (2006).
88.
EleutérioJ.Jr, Giraldo, P. C., Gonçalves, A. K., Cavalcante, D. I., de Almeida Ferriera, F. V., Mesquita, S. M., Morais, S. S. Prognostic markers of high-grade squamous intraepithelial lesions: The role of p16INK4a and high-risk Human Papillomavirus. Acta Obstet Gynecol Scand86, 94–98 (2007).
89.
WentzensesN.BergeronC.CasF.EschenbachD.VinokurovaS.von KnebelD. M.Evalutation of a nuclear score for p16 INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer105, 461–467 (2005).
90.
Wise-DraperT. M.WellsS. I.Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci1, 1003–1017 (2008).
91.
AsadurianYKurilinH.LichtigH.JackmanA.GonenP.TommasinoM.ZehbeI.ShermanL.Activities of human papillomavirus 16 E6 natural variants in human keratinocytes. J Med Virol79, 1751–1760 (2007).
92.
VarnaiA. D.BollmannM.BankfalviA.SpeichN.SchmittC.GriefingholtH.KovácsK.KlozorisC.BollmannR.Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: Diagnostic and prognostic implications. Oncol Report19, 457–465 (2008).
93.
MoldenT.KrausI.SkomedalH.NordstrømT.KarlsenF.PreTect™ HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Meth142, 204–212 (2007).
94.
CuschieriK. S.BeattieG.HassanS.RobertsonK.CubieH. A.Assessment of human papillomavirus mRNA detection over time in cervical specimens collected in liquid based cytology medium. J Virol Methods124: 211–215 (2005).
95.
NakagawaS.YoshikawaH.YasugiT.KimuraM.KawanaK.MatsumotoK.YamadaM.OndaT.TaketaniY.Ubiquitous presence of E6 and E7 transcrips in human papillomavirus-positive cervical carcinoma regardless of its type. J Med Virol62, 251–258 (2000).
96.
SkomedalH.KrausI.SilvaI.MoldenT.HovlandS.MorlandG.MorlandE.KarlsenF.Direct Detection of Cervical Carcinogenesis through mRNA, in Emerging issues on HPV infections: from science to practice, pp. 82–102. Ed., JosephMonsonegoKarger. Paris (2006).
97.
LieA. K.RisbergT. B.BorgeB.SandstadB.DelabieJ.RimalaR.OnsrudM.ThoresenS.DNA- versus RNA-based methods for human Papillomavirus detection in cervical neoplasia. Gynecol Oncol97, 908–915 (2005).
98.
WeltersM. J.KenterG. G.PiersmaS. J.VloonA. P.LöwikM. J.Berends-van der MeerD. M.DrijfhoutJ. W.ValentijnA. R.WafelmanA. R.OostendorpJ.FleurenG. J.OffringaR.MeliefC. J.van der BurgS. H.Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. Clin Cancer Res14, 178–187 (2008).
99.
SchillerJ. T.DouglasR. L.Perspectives on HPV virus-like particle Vaccine efficacy, in Emerging issues on HPV infections: from science to practice, pp. 2217–226. Ed., JosephMonsonegoKarger. Paris (2006).
